keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LQVTDSGLYRCVIYHPP (LP17) TFA is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that notably mitigates ischemic infarction and neuronal damage. This compound is capable of penetrating the brain to inhibit TREM-1 [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | LQVTDSGLYRCVIYHPP (LP17) TFA is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that notably mitigates ischemic infarction and neuronal damage. This compound is capable of penetrating the brain to inhibit TREM-1 [1]. |
In vitro | LQVTDSGLYRCVIYHPP (LP17) at concentrations of 1 or 10 μM for 24 hours significantly reduced the mRNA levels of pro-inflammatory cytokines and chemokines following reoxygenation and notably decreased the extracellular protein levels of IL-1β and IL-18 in a model of oxygen-glucose deprivation (OGD) in microglia [1]. Additionally, LP17 (10 μM; 24 hours) interacted with the microglial spleen tyrosine kinase (SYK) [1]. |
In vivo | LP17 (0.5 or 1 mg/kg; intranasal; once daily for 3 days) alleviated ischemia-induced infarction and neuronal damage in mice [1]. |
Molecular Weight | 2075.27 |
Formula | C91H138F3N23O27S |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LQVTDSGLYRCVIYHPP TFA inhibitor inhibit